Efficacy of rabbit antithymocyte globulin as first-line treatment of severe aplastic anemia: an Asian multicenter retrospective study

Suporn Chuncharunee, Raymond Wong, Ponlapat Rojnuckarin, Cheng Shyong Chang, Kian Meng Chang, Meng Yao Lu, Wen Li Hwang, Liang Piu Koh, Tsai-Yun Chen, Anskar Yh Leung, Lalita Norasetthada, Shih Chung Wang, Ming Chih Chang, Kang Hsi Wu, Surapol Issaragrisil

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Due to the unavailability of horse antithymocyte globulin (ATG) in many markets worldwide, patients with severe aplastic anemia (SAA) are limited to the use of rabbit ATG. We aimed to analyze hematologic response and overall survival (OS) of Asian patients treated with rabbit ATG as first-line therapy of SAA. We retrospectively reviewed the medical records of 97 consecutive patients who received rabbit ATG as first-line treatment of SAA from 2006 to 2012 at centers in four Asian countries. The primary endpoint was 6- and 12-month overall response rates (ORR) for patients receiving rabbit ATG within the recommended dose range (2.5–3.75 mg/kg/day). Secondary endpoints included ORR in patients receiving any dose of rabbit ATG and 2-year OS. For patients who received rabbit ATG within the recommended dose range, 6- and 12-month ORRs were 17.4 and 63.6 %, respectively. For patients who received any dose of rabbit ATG, 6- and 12-month ORRs were 24.3 and 68.6 %, respectively. The 2-year OS rate was 86.3 %. Rabbit ATG is effective for treatment of SAA in Asian patients. The 12-month ORR and 2-year OS with rabbit ATG were comparable to historical results obtained with horse ATG.

Original languageEnglish
Pages (from-to)454-461
Number of pages8
JournalInternational Journal of Hematology
Volume104
Issue number4
DOIs
Publication statusPublished - 2016 Oct 1

Fingerprint

Antilymphocyte Serum
Aplastic Anemia
Multicenter Studies
Retrospective Studies
Rabbits
Therapeutics
Horses
Survival
Medical Records
Survival Rate

All Science Journal Classification (ASJC) codes

  • Hematology

Cite this

Chuncharunee, Suporn ; Wong, Raymond ; Rojnuckarin, Ponlapat ; Chang, Cheng Shyong ; Chang, Kian Meng ; Lu, Meng Yao ; Hwang, Wen Li ; Koh, Liang Piu ; Chen, Tsai-Yun ; Leung, Anskar Yh ; Norasetthada, Lalita ; Wang, Shih Chung ; Chang, Ming Chih ; Wu, Kang Hsi ; Issaragrisil, Surapol. / Efficacy of rabbit antithymocyte globulin as first-line treatment of severe aplastic anemia : an Asian multicenter retrospective study. In: International Journal of Hematology. 2016 ; Vol. 104, No. 4. pp. 454-461.
@article{1aeba19847d141f2b2e30724ebd1c4cb,
title = "Efficacy of rabbit antithymocyte globulin as first-line treatment of severe aplastic anemia: an Asian multicenter retrospective study",
abstract = "Due to the unavailability of horse antithymocyte globulin (ATG) in many markets worldwide, patients with severe aplastic anemia (SAA) are limited to the use of rabbit ATG. We aimed to analyze hematologic response and overall survival (OS) of Asian patients treated with rabbit ATG as first-line therapy of SAA. We retrospectively reviewed the medical records of 97 consecutive patients who received rabbit ATG as first-line treatment of SAA from 2006 to 2012 at centers in four Asian countries. The primary endpoint was 6- and 12-month overall response rates (ORR) for patients receiving rabbit ATG within the recommended dose range (2.5–3.75 mg/kg/day). Secondary endpoints included ORR in patients receiving any dose of rabbit ATG and 2-year OS. For patients who received rabbit ATG within the recommended dose range, 6- and 12-month ORRs were 17.4 and 63.6 {\%}, respectively. For patients who received any dose of rabbit ATG, 6- and 12-month ORRs were 24.3 and 68.6 {\%}, respectively. The 2-year OS rate was 86.3 {\%}. Rabbit ATG is effective for treatment of SAA in Asian patients. The 12-month ORR and 2-year OS with rabbit ATG were comparable to historical results obtained with horse ATG.",
author = "Suporn Chuncharunee and Raymond Wong and Ponlapat Rojnuckarin and Chang, {Cheng Shyong} and Chang, {Kian Meng} and Lu, {Meng Yao} and Hwang, {Wen Li} and Koh, {Liang Piu} and Tsai-Yun Chen and Leung, {Anskar Yh} and Lalita Norasetthada and Wang, {Shih Chung} and Chang, {Ming Chih} and Wu, {Kang Hsi} and Surapol Issaragrisil",
year = "2016",
month = "10",
day = "1",
doi = "10.1007/s12185-016-2053-8",
language = "English",
volume = "104",
pages = "454--461",
journal = "International Journal of Hematology",
issn = "0925-5710",
publisher = "Springer Japan",
number = "4",

}

Chuncharunee, S, Wong, R, Rojnuckarin, P, Chang, CS, Chang, KM, Lu, MY, Hwang, WL, Koh, LP, Chen, T-Y, Leung, AY, Norasetthada, L, Wang, SC, Chang, MC, Wu, KH & Issaragrisil, S 2016, 'Efficacy of rabbit antithymocyte globulin as first-line treatment of severe aplastic anemia: an Asian multicenter retrospective study', International Journal of Hematology, vol. 104, no. 4, pp. 454-461. https://doi.org/10.1007/s12185-016-2053-8

Efficacy of rabbit antithymocyte globulin as first-line treatment of severe aplastic anemia : an Asian multicenter retrospective study. / Chuncharunee, Suporn; Wong, Raymond; Rojnuckarin, Ponlapat; Chang, Cheng Shyong; Chang, Kian Meng; Lu, Meng Yao; Hwang, Wen Li; Koh, Liang Piu; Chen, Tsai-Yun; Leung, Anskar Yh; Norasetthada, Lalita; Wang, Shih Chung; Chang, Ming Chih; Wu, Kang Hsi; Issaragrisil, Surapol.

In: International Journal of Hematology, Vol. 104, No. 4, 01.10.2016, p. 454-461.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Efficacy of rabbit antithymocyte globulin as first-line treatment of severe aplastic anemia

T2 - an Asian multicenter retrospective study

AU - Chuncharunee, Suporn

AU - Wong, Raymond

AU - Rojnuckarin, Ponlapat

AU - Chang, Cheng Shyong

AU - Chang, Kian Meng

AU - Lu, Meng Yao

AU - Hwang, Wen Li

AU - Koh, Liang Piu

AU - Chen, Tsai-Yun

AU - Leung, Anskar Yh

AU - Norasetthada, Lalita

AU - Wang, Shih Chung

AU - Chang, Ming Chih

AU - Wu, Kang Hsi

AU - Issaragrisil, Surapol

PY - 2016/10/1

Y1 - 2016/10/1

N2 - Due to the unavailability of horse antithymocyte globulin (ATG) in many markets worldwide, patients with severe aplastic anemia (SAA) are limited to the use of rabbit ATG. We aimed to analyze hematologic response and overall survival (OS) of Asian patients treated with rabbit ATG as first-line therapy of SAA. We retrospectively reviewed the medical records of 97 consecutive patients who received rabbit ATG as first-line treatment of SAA from 2006 to 2012 at centers in four Asian countries. The primary endpoint was 6- and 12-month overall response rates (ORR) for patients receiving rabbit ATG within the recommended dose range (2.5–3.75 mg/kg/day). Secondary endpoints included ORR in patients receiving any dose of rabbit ATG and 2-year OS. For patients who received rabbit ATG within the recommended dose range, 6- and 12-month ORRs were 17.4 and 63.6 %, respectively. For patients who received any dose of rabbit ATG, 6- and 12-month ORRs were 24.3 and 68.6 %, respectively. The 2-year OS rate was 86.3 %. Rabbit ATG is effective for treatment of SAA in Asian patients. The 12-month ORR and 2-year OS with rabbit ATG were comparable to historical results obtained with horse ATG.

AB - Due to the unavailability of horse antithymocyte globulin (ATG) in many markets worldwide, patients with severe aplastic anemia (SAA) are limited to the use of rabbit ATG. We aimed to analyze hematologic response and overall survival (OS) of Asian patients treated with rabbit ATG as first-line therapy of SAA. We retrospectively reviewed the medical records of 97 consecutive patients who received rabbit ATG as first-line treatment of SAA from 2006 to 2012 at centers in four Asian countries. The primary endpoint was 6- and 12-month overall response rates (ORR) for patients receiving rabbit ATG within the recommended dose range (2.5–3.75 mg/kg/day). Secondary endpoints included ORR in patients receiving any dose of rabbit ATG and 2-year OS. For patients who received rabbit ATG within the recommended dose range, 6- and 12-month ORRs were 17.4 and 63.6 %, respectively. For patients who received any dose of rabbit ATG, 6- and 12-month ORRs were 24.3 and 68.6 %, respectively. The 2-year OS rate was 86.3 %. Rabbit ATG is effective for treatment of SAA in Asian patients. The 12-month ORR and 2-year OS with rabbit ATG were comparable to historical results obtained with horse ATG.

UR - http://www.scopus.com/inward/record.url?scp=84976908629&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84976908629&partnerID=8YFLogxK

U2 - 10.1007/s12185-016-2053-8

DO - 10.1007/s12185-016-2053-8

M3 - Article

C2 - 27376944

AN - SCOPUS:84976908629

VL - 104

SP - 454

EP - 461

JO - International Journal of Hematology

JF - International Journal of Hematology

SN - 0925-5710

IS - 4

ER -